PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

NARecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Cardiac Amyloidosis
Interventions
COMBINATION_PRODUCT

Telemonitoring service

Patients in the active arm will receive a cellular network connected set of digital scales, and instructed to take their weight each morning at the same time. This device (BodyTrace) automatically uploads each daily weight reading to a central database. A clinical algorithm is applied to detect those at risk of acute and subacute decompensated heart failure. Patients are contacted within 24-48 hours of being flagged as at risk by a heart failure specialist. A clinical history is taken, and medication review undertaken, in line with a protocol. Diuretics are adjusted as per the protocolised changes, or for patients at ceiling of treatment, referral for local specialist review is made. A third protocol for follow-up is then followed to close the loop of intervention.

Trial Locations (1)

SW17 0RE

RECRUITING

Richmond Research Institute, London

All Listed Sponsors
collaborator

Richmond Pharmacology Limited

INDUSTRY

collaborator

National Amyloidosis Centre

UNKNOWN

lead

Richmond Research Institute

INDUSTRY